Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6231)	11/6/1998 6:21:00 PM
From: BigKNY3	Read Replies (3) \| Respond to of 9523

Pfizer -5: Seeks To Combat Osteoporosis, Cancer >PFE 11/06/98 Dow Jones News Service In the early stages of development, Pfizer has expanded into new therapeutic areas. The company is studying effective cancer tumor control and has seen "highly encouraging results." A compound called CP-358,774 has just entered Phase II clinical research as a potential agent to prevent the rapid growth of cancer cells. Another compound, ezlopitant, is in Phase II clinical trials to help patients better tolerate their anti-cancer therapy. Pfizer is also tackling obesity and has three candidates in pre-clinical or early clinical development. And the company is attempting to combat the effects of aging, with two selective estrogen receptor modulators under development. One, droloxifene, has demonstrated efficacy in treating breast cancer and has shown in clinical trials that it significantly increases bone mass in normal patients and those with osteoporosis. A second selective estrogen receptor modulator could prove to have even greater potential, Pfizer said. One of the two candidates will be chosen to enter Phase III clinical trials next year. Pfizer is also making strides in diabetes. Just this week, the company announced plans with Hoechst Marion Roussel Ltd. to jointly manufacture insulin and co-develop and co-promote inhaled insulin. The company touted a broad portfolio in its Animal Health group product pipeline, noting 43 drug candidates are in development.